Growth Hormone Receptor Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Growth hormone receptor (GHR) is a transmembrane protein consisting of 620 amino acids. The receptor is part of the Type I cytokine receptor family of receptors. This gene encodes a protein that is a transmembrane receptor for growth hormone. The binding of growth hormone to the receptor leads to the reorientation of a pre-assembled receptor dimer dimerization and the activation of an intra- and intercellular signal transduction pathway leading to growth agonist mimics the action as performed by the growth hormone in the body. The mechanism of action (MOA) of the GHR agonist is by binding GHR dimerizes and interacts with Janus kinase 2 (JAK2), subsequently leading to tyrosine phosphorylation of JAK2 and the GH receptor.

The signal transducer activator of the transcription (STAT) pathway is initiated, where transcription factors such as STAT1, STAT3, and STAT5 are translocated into the nucleus to stimulate target gene transcription. At the epiphysis or growth plate, growth hormone increases linear growth by promoting differentiation of pre-chondrocytes and expansion of osteoblasts and binding to its receptor in the liver and cartilage promotes the production of IGF-1, which acts on type 1 IGF receptors to also stimulate linear growth. GHR Agonists are used in the treatment of bone diseases, dwarfism, endocrine system diseases, brain diseases, pituitary diseases, growth diseases, heart diseases, gonadal disorders, infertility, and obesity among others. Increased prevalence of bone and endocrine disorders and increased R&D investment are the key drivers for the GHR Agonist market. For instance, according to the National Organization for Rare Disorders 2021, it has been estimated that achondroplasia is the most commonly occurring abnormality of bone growth (skeletal dysplasia), occurring in approximately 1 in 20,000-30,000 live births. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in GHR Agonist. For instance, Novo Nordisk launched Norditropin (Somatropin) for the treatment of growth hormone deficiencies in children and adults. Moreover, to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instance, Lateral Pharma’s LAT8881 for the indication of neuropathic pain is under the various stages of clinical studies.

Key Market Developments:

  • In February 2018, Ferring Pharma received FDA approval for Zomacton (Somatropin) injection for the replacement of growth hormone (GH) in adults with GH deficiency.
  • In August 2021, Ascendis Pharma received FDA approval for Skytrofa (Lonapegsomatropin-Tcgd) for pediatric patients having growth failure due to inadequate secretion of endogenous growth hormone.
  • In June 2023, Pfizer in global collaboration with OPKO Health received FDA approval for Ngenla (Somatrogon-Ghla) for the treatment of growth hormone deficiency.

Approved Drug Molecules and Brand Names for GHR Agonist:

  • Norditropin (Somatropin)
  • Zorbtive (Somatropin)
  • Nutropin AQ (Somatropin)
  • Genotropin (Somatropin)
  • Ngenla (Somatrogon-Ghla)
  • Skytrofa (Lonapegsomatropin-Tcgd)
  • Egrifta (Tesamorelin Acetate)
  • Jintropin (Recombinant Human Growth Hormone)
  • Omnitrope (Somatotropin)
  • Zomacton (Somatropin)

Drugs under the Pipeline for GHR Agonist:

  • Sogroya (Somapacitan)
  • Tev-Tropin (JR-401S)
  • Macrilen (Macimorelin)
  • Somavaratan (VRS-317)
  • LAT8881
  • Eutropin Plus (Somatropin SR)
  • Growtropin-II (Somatropin Biosimilar)
  • Pegylated Somatropin (LA Growth Hormone)
  • Albutropin (TV-1106)
  • Valtropin (Somatropin Biosimilar)
  • Efpegsomatropin (HM10560A)
  • Eftansomatropin Alfa (GX-H9)
  • Accretropin (Somatropin)
  • Maxomat (Somatropin)
  • ALRN-5281
  • ALT-P1 (Somatropin Biosimilar)
  • PEG-Somatropin (ARX201)
  • Syntropin (Somatropin Biosimilar)
  • Viador-Hpth (1-34)
  • Vitatropin (HL032)
  • hGH-DepoFoam (Somatropin)
  • rhGH-Emisphere (Somatropin Oral, Oral Recombinant Human Growth Hormone)

Clinical Activity and Developments of GHR Agonist:

Up until July 2023, there will be about 41 companies with over 34 compounds that focus on various forms of bone diseases and CNS disorders. For these molecules, more than 60 clinical trials are being conducted and the majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,

  • In September 2020, Lateral Pharma completed phase 2a of the oral LAT8881 clinical trial study to evaluate safety and efficacy in Neuropathic pain.
  • In April 2023, AEterna Zentaris has completed phase 2, a pilot clinical trial of repeated doses of Macimorelin to evaluate safety and efficacy in patients with cancer cachexia.

Molecule Name

Number of Studies

Sogroya (Somapacitan)


Tev-Tropin (JR-401S)


Macrilen (Macimorelin)


Somavaratan (VRS-317)




Target Indication Analysis of GHR Agonist:

The molecules such as Ngenla (Somatrogon-Ghla) developed by Pfizer in global collaboration with OPKO Health for the line of treatment for the treatment of patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Ascendis Pharma’s Skytrofa (Lonapegsomatropin-Tcgd) for pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone. Moreover, Genentech’s Nutropin AQ (Somatropin) for the treatment of children with growth failure due to growth hormone deficiency (GHD), idiopathic short stature (ISS), Turner syndrome (TS), and chronic kidney disease (CKD) up to the time of renal transplantation and approved for the treatment of adults with either childhood-onset or adult-onset GHD.

Frequently Asked Questions

Ngenla (Somatrogon-Ghla), Skytrofa (Lonapegsomatropin-Tcgd), and Norditropin (Somatropin), are the few FDA-approved GHR Agonist.

Novo Nordisk, EMD Serono, Ipsen, Roche, and Pfizer are few leading market players in GHR Agonist Market.

Bone disorders, dwarfism, endocrine system diseases, brain diseases, pituitary diseases, growth diseases, heart diseases, gonadal disorder, infertility, obesity, etc are the major indication of GHR agonists.

There are a total of 22 molecules that are in the Phase-1, Phase-2 and Phase-3 clinical development for GHR agonist.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Novo Nordisk
  • EMD Serono
  • Ipsen
  • Roche
  • Pfizer
  • Theratechnologies
  • Genescience
  • Ascendis
  • Opko Health
  • Novartis
  • Ferring
  • Sanofi
  • Teva
  • Hanmi
  • Genexine
  • Apotex
  • Syneron Medical
  • Eli Lilly
  • Pacira

Adjacent Markets